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In this case report, we describe a refractory CMML case without eosinophilia harboring a PDGFRB re-
arrangement leading to a favorable response with imatinib. We believe this case demonstrates the utility
of broad spectrum genomic proﬁling in refractory CMML cases as an opportunity to uncover additional
treatment options.
& 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Chronic Myelomonocytic Leukemia (CMML) with eosinophilia
has been historically associated with rearrangements of PDGFRA or
B [1,2]. Although this entity has now been reclassiﬁed as distinct
from CMML by the World Health Organization (WHO) [3], clin-
icians reserve routine evaluation of PDGFR rearrangements in
suspected CMML cases with eosinophilia because this genetic le-
sion predicts response to imatinib. A recent article by Cheah et al.
report durable long-term remissions with the use of imatinib in a
collection of patients with myeloid malignancies bearing PDGFRB
fusions [4]. They conﬁrm that the formation of PDGFRB fusion
genes secondary to rearrangement of PDGFRB at 5q31-33 con-
stitutively activates the PDGFRB receptor tyrosine kinase and are
exquisitely sensitive to treatment with imatinib [1,5] All patients
in this report had eosinophilia at diagnosis which likely triggered
the evaluation for a possible PDGFRB fusion. Given the limited
armamentarium available for CMML, we perform broad spectrum
genomic proﬁling to include analysis of PDGFRB in those cases that
have failed standard therapies and have no clinical trial options.
Using this strategy, we report a refractory CMML case for which a
novel PDGFRB fusion was identiﬁed by next generation sequencing
in a refractory CMML case without eosinophilia that achieved a
favorable response with imatinib.
A 77-year-old woman was referred to our medical center for
second opinion for refractory CMML-2. She had been incidentally
found to have mild leukocytosis, anemia, and thrombocytosis on
routine laboratory analysis. At diagnosis her white blood cell count
(WBC) was 12109/L, hemoglobin was 10.8 g/dL, and plateletLtd. This is an open access article u
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).count was 420109/L. Monocytes and eosinophils constituted 19%
and 1% of total WBC, respectively. Bone marrow biopsy demon-
strated hypercellularity, bone marrow dysplasia, and 14% blasts
consistent with a diagnosis of CMML-2. Cytogenetics were 46,XX,
del(7)(q22q32) and no other analysis to interrogate PDGFR re-
arrangements was performed at that time.
After two cycles of 5-azacitidine, the patient proceeded to un-
dergo matched unrelated donor allogeneic hematopoietic stem
cell transplantation but subsequently had graft failure and re-
lapsed in a CMML-2 state. Post-transplant therapies included
5-azacitidine, induction chemotherapy, and decitabine for which
she did not respond. Broad spectrum molecular proﬁling was
performed using the clinically available FoundationOnesHeme
assay which analyzes the complete coding DNA sequences of 405
genes, selected introns of 31 genes involved in rearrangements,
and the RNA sequence of 265 commonly rearranged genes to
identify gene fusions. Findings included mutations in NRAS,
RUNX1, ASXL1, IKZF1, and a SDPR-PDGFRB rearrangement. SDPR is a
gene that encodes a phospholipid-binding protein that has not
been previously reported to partner with PDGFRB [4,6]. Given that
SDPR is highly expressed in hematopoietic early progenitor cells
(Fig. 1) [7,8], we hypothesized that the fusion of the SDPR pro-
moter to the PDGFRB coding regionwould result in overexpression
of PDGFRB as has been reported with other fusions. Her peripheral
eosinophil count at the time of molecular proﬁling was 1.12 k/L
and bone marrow biopsy was consistent with secondary AML with
36% blasts. The patient was started on 400 mg of imatinib and
achieved a signiﬁcant reduction in bone marrow blasts to 5%,
consistent with a partial CR. Blood counts at time consisted of
white blood cell count of 3 k/mL, platelets of 108 k/mL, hemoglobin
of 8.5 g/dL and hematocrit of 25.9%. The duration of response using
imatinib was approximately 4 months prior to disease progressionnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. SDPR expression for various hematopoietic cells. Each dot in the plot
corresponds to the expression of SDPR in a microarray. Horizontal lines represent
the median expression for each class of cells. Expression is given on y-axis on a log2
scale. HSC_BM, Hematopoietic stem cells from bone marrow; early HPC_BM,
Hematopoietic progenitor cells from bone marrow; CMP, Common myeloid pro-
genitor cell; GMP, Granulocyte monocyte progenitors; MEP, Megakaryocyte-ery-
throid progenitor cell; PM_BM, Promyelocyte from bone marrow; MY_BM, Mye-
locyte from bone marrow; PMN_BM, Polymorphonuclear cells from bone marrow;
PMN_PB, Polymorphonuclear cells from peripheral blood; CD14þ monocytes,
CD14þ Monocytes; B cells, CD19þ B cells; CD4þ T cells, CD4þ T cells; CD8þ T
cells, CD8þ T cells; NK cells, CD56þ natural killer cells; mDC, CD11cþ myeloid
dendritic cells; pDC, CD123þ plasmacytoid dendritic cells.
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hydroxyurea and expired 3.5 months later.
CMML remains a lethal malignancy with limited treatment
options. The incidence of PDGFRB rearrangements in myeloproli-
ferative neoplasms (MPNs) is low; a recent study reported only
1.8% of 556 patients evaluated [2]. While MPNs with PDFGRB re-
arrangements are phenotypically diverse, CMML with eosinophilia
is a common morphologic diagnosis [2,4]. We report a case of a
refractory CMML case without eosinophilia harboring a PDGFRBrearrangement leading to a favorable response with imatinib. This
case demonstrates the utility of broad spectrum genomic proﬁling
in refractory CMML cases as an opportunity to uncover additional
treatment options.Contribution
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